Does tocilizumab contribute to elevation of rheumatoid factor and induction of paradoxical syaloadenitis in rheumatoid arthritis patients?

about

Does tocilizumab contribute to elevation of rheumatoid factor and induction of paradoxical syaloadenitis in rheumatoid arthritis patients?

Item

http://www.wikidata.org/entity/Q42254666

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Does tocilizumab contribute to ...... rheumatoid arthritis patients?

@en

Does tocilizumab contribute to ...... rheumatoid arthritis patients?

@nl

type

Item

label

Does tocilizumab contribute to ...... rheumatoid arthritis patients?

@en

Does tocilizumab contribute to ...... rheumatoid arthritis patients?

@nl

prefLabel

Does tocilizumab contribute to ...... rheumatoid arthritis patients?

@en

Does tocilizumab contribute to ...... rheumatoid arthritis patients?

@nl

P1476

Does tocilizumab contribute to ...... rheumatoid arthritis patients?

@en

P2093

Daniela Marasović Krstulović

http://www.w3.org/2001/XMLSchema#string

Dijana Perković

http://www.w3.org/2001/XMLSchema#string

Dušanka Martinović Kaliterna

http://www.w3.org/2001/XMLSchema#string

Ivanka Marinović

http://www.w3.org/2001/XMLSchema#string

Jure Aljinović

http://www.w3.org/2001/XMLSchema#string

P2860

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials.

Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients

Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement

Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome

Interleukin-6 as a key player in systemic inflammation and joint destruction.

Tocilizumab: therapy and safety management.

P2888

s00508-013-0460-x

P304

126-129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00508-013-0460-X

http://www.w3.org/2001/XMLSchema#string

P433

3-4

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P50

Tonko Vlak

P577

2013-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258702673

http://www.w3.org/2001/XMLSchema#string

P698

24249328

http://www.w3.org/2001/XMLSchema#string